New research suggests that people who come off new slimming jabs like Wegovy and Mounjaro tend to recover reduced body mass much more quickly than those who stop traditional diet and exercise programs.
Published data in a major medical journal shows that while overweight people frequently drop a large proportion of their total mass while on the medication, the weight comes back at an average rate of nearly a kilo each month once they quit.
"People purchasing these drugs must be cognizant of the potential of rapid weight regain when the medication is stopped," stated researcher Dr. Susan Jebb.
That rate of recovery implies a return to pre-treatment weight in about one and a half years.
Comparing Therapies
The study, which reviewed dozens of trials involving over 9,000 of patients, compared the results of GLP-1 agonists with other pills.
The team emphasize that people who lose weight through diet and exercise generally see a slower weight regain—around 0.1 kg a month—after stopping.
Explaining the Rapid Regain
Experts propose the mechanism of the injections accounts for the heightened rebound.
GLP-1 drugs imitate a natural hormone called GLP-1, which helps regulate appetite.
"Artificially providing the hormone levels several times higher than normal could lead to the body to generate a reduced amount of its own natural hormone, and may also lessen responsiveness to its actions," said Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this hormone supplement results in appetite is uncontrolled, making overeating much more probable."
An Ongoing Issue?
The NHS recommend the injections for people with weight-linked health risks, alongside recommended diet and exercise modifications.
Professionals contend that, due to the significant potential of weight regain, the treatment might need to be life-long.
This perspective is echoed by pharmaceutical companies, who say that the results "highlight the long-term nature of obesity," comparing it to managing diseases like high blood pressure.
User Experiences
Individuals who have stopped the jabs explain a sudden resurgence of cravings.
"It was like a trigger that goes on and you become starving," said an individual.
This difficulty is compounded if patients have not established permanent dietary or behavioural changes during treatment.
Widespread Interest
Figures indicate that a significant number of people in the UK have used these injections in the last 12 months, with demand continuing to grow.
- Adoption is more common among women compared to males.
- The 40s and 50s demographic shows the highest usage rates.
- A large proportion obtain the medications through private prescriptions rather than public health services.
Ultimately, clinicians emphasize that while these medications are potent tools for weight loss, they are not a magic solution and lasting health benefits likely depends on integrated behavioural changes.